669002-29-3Relevant articles and documents
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy
Thomson, Stephen A.,Banker, Pierette,Bickett, D. Mark,Boucheron, Joyce A.,Carter, H. Luke,Clancy, Daphne C.,Cooper, Joel P.,Dickerson, Scott H.,Garrido, Dulce M.,Nolte, Robert T.,Peat, Andrew J.,Sheckler, Lauren R.,Sparks, Steven M.,Tavares, Francis X.,Wang, Liping,Wang, Tony Y.,Weiel, James E.
scheme or table, p. 1177 - 1182 (2009/09/04)
Key binding interactions of the anthranilimide based glycogen phosphorylase a (GPa) inhibitor 2 from X-ray crystallography studies are described. This series of compounds bind to the AMP site of GP. Using the binding information the core and the phenyl ur
New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
-
Page/Page column 37, (2010/02/09)
The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1, R2, R3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
